Hanall Biopharma Co., Ltd. (KRX: 009420)

Hanall Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	17,741	33,723	16,841	12,794	4,200	6,120
Short-Term Investments	-	-	10,000	-	-	89,313
Trading Asset Securities	18,244	22,775	27,093	67,775	86,505	-
Cash & Short-Term Investments	35,985	56,497	53,934	80,570	90,706	95,433
Cash Growth	-33.20%	4.75%	-33.06%	-11.17%	-4.95%	6.80%
Accounts Receivable	16,949	15,630	26,689	9,861	11,553	15,720
Other Receivables	5,494	6,894	4,021	5,694	4,175	6,910
Receivables	22,443	22,524	30,709	15,555	15,729	22,630
Inventory	30,786	32,384	25,184	20,408	19,891	13,717
Prepaid Expenses	182.67	93.41	126.5	141.46	142.88	31.99
Other Current Assets	2,048	2,078	1,835	2,141	2,896	2,482
Total Current Assets	91,444	113,577	111,789	118,815	129,365	134,295
Property, Plant & Equipment	18,361	19,434	19,126	19,045	15,480	14,936
Long-Term Investments	45,705	59,626	39,315	23,990	52,779	17,929
Other Intangible Assets	41,107	1,826	2,063	2,219	2,597	3,051
Long-Term Accounts Receivable	-	-	0	-0	-0	0
Long-Term Deferred Tax Assets	9,830	6,978	8,549	12,220	3,203	6,894
Long-Term Deferred Charges	-	30,783	21,776	16,877	12,481	7,666
Other Long-Term Assets	6,159	7,512	10,833	5,312	4,228	6,611
Total Assets	212,914	239,747	213,451	198,478	220,132	191,383
Accounts Payable	5,510	11,273	4,755	1,759	4,946	4,300
Accrued Expenses	2,664	3,039	2,123	2,147	2,105	1,867
Current Portion of Leases	669.74	700.22	559.34	423.43	274.76	367.49
Current Income Taxes Payable	-	356.7	919.83	94.87	818.23	1,238
Other Current Liabilities	20,321	22,284	20,178	17,695	14,925	19,612
Total Current Liabilities	29,164	37,652	28,535	22,120	23,069	27,385
Long-Term Leases	481.81	590.31	751.06	911.68	276.76	200.69
Other Long-Term Liabilities	12,969	15,286	15,909	11,954	15,513	23,381
Total Liabilities	42,615	53,529	45,195	34,986	38,859	50,966
Common Stock	26,120	26,120	26,120	26,120	26,120	26,120
Additional Paid-In Capital	115,384	115,040	112,800	112,777	112,489	112,354
Retained Earnings	27,715	31,362	29,409	26,379	17,587	-3,109
Treasury Stock	-13,072	-13,205	-13,228	-3,254	-3,339	-3,347
Comprehensive Income & Other	14,152	26,902	13,156	1,469	28,416	8,399
Shareholders' Equity	170,299	186,218	168,256	163,492	181,273	140,417
Total Liabilities & Equity	212,914	239,747	213,451	198,478	220,132	191,383
Total Debt	1,152	1,291	1,310	1,335	551.51	568.18
Net Cash (Debt)	34,833	55,207	52,624	79,234	90,154	94,865
Net Cash Growth	-33.79%	4.91%	-33.58%	-12.11%	-4.97%	6.17%
Net Cash Per Share	688.29	1089.06	1035.58	1547.46	1761.59	1853.67
Filing Date Shares Outstanding	50.71	50.69	50.69	51.21	51.18	51.18
Total Common Shares Outstanding	50.71	50.69	50.69	51.21	51.18	51.18
Working Capital	62,280	75,925	83,254	96,695	106,295	106,910
Book Value Per Share	3358.38	3673.44	3319.29	3192.82	3541.94	2743.77
Tangible Book Value	129,193	184,392	166,193	161,273	178,676	137,366
Tangible Book Value Per Share	2547.74	3637.42	3278.59	3149.48	3491.19	2684.14
Land	-	1,494	1,494	1,494	1,494	1,494
Buildings	-	17,417	17,363	14,968	14,694	12,644
Machinery	-	16,638	16,546	14,294	14,997	14,530
Construction In Progress	-	514.54	101.28	3,603	18.98	858.14

Source: S&P Capital IQ. Standard template. Financial Sources.